Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

Lifecycle validation in regulated manufacturing requires structured process design, risk-based qualification, and continued process verification. This guide explains how PPQ, CPP control, and ongoing GMP monitoring reduce compliance risk and strengthen inspection readiness across pharmaceutical operations.
Inspection trends continue to highlight weaknesses in pharmaceutical documentation hierarchy and procedural governance. This article analyzes how SOP hierarchy in pharma, work instruction in GMP, and GMP document control systems influence audit readiness, data integrity risk, and CAPA effectiveness.
Pharmaceutical supply chain roles now carry direct regulatory and commercial impact. This article examines how demand, salaries, and career paths evolve across regulated logistics, distribution, and global supply networks, helping professionals understand where hiring pressure concentrates and why compensation continues
Pharmaceutical supply chain companies play a critical role in compliant sourcing, storage, and global distribution. This article explores how pharma logistics companies manage cold chain control, regulatory expectations, and complex pharmaceutical distribution networks across highly regulated healthcare markets.
GMP inspections frequently identify facility and environmental control weaknesses as root causes of compliance risk. This article examines how cleanroom standards, layout decisions, and documentation influence contamination control, inspection readiness, and regulatory expectations across pharmaceutical manufacturing environments.
GMP inspections frequently identify facility and environmental control weaknesses as root causes of compliance risk. This article examines how cleanroom standards, layout decisions, and documentation influence contamination control, inspection readiness, and regulatory expectations across pharmaceutical manufacturing environments.
Regulatory inspections increasingly reveal that quality failures stem from governance and oversight gaps, not technical errors. This article explains how quality systems, documentation, and inspection readiness shape compliance outcomes in regulated pharmaceutical manufacturing environments.
EMA nitrosamine Appendix 1 has reshaped how inspectors assess risk, justification, and lifecycle oversight. This article explains what regulators review during GMP inspections, how expectations apply in practice, and why governance gaps often escalate nitrosamine-related findings.